Report on the antiemetic effectivity of a single 1 mg oral granisetron in moderately emetogenic chemotherapies of gynecological malignancies.
On the basis of the relatively long 9-12 hour plasma-half-life of the highly selective serotonin antagonist granisetron (GRAN) and on observations that emetic episodes are detected mainly 10 hours after starting chemotherapy it was supposed that a single 1 mg oral GRAN (Kytril, SmithKline Beecham) is enough to prevent the emesis of moderately emetogenic chemotherapies. A total of 45 gynecological cancer patients were treated in 115 chemotherapy cycles with a single 1 mg oral GRAN in a prospective, non-randomized study. Patients stayed in hospital for 24 hours after chemotherapy and emetic episodes were registered on special charts. A complete response (CR) of 83.4% was found in the 115 cycles. Thirty-seven of the total 45 patients with ovarian cancer had a 84.7% CR in the first 24 hours of chemotherapy. In 29 patients 50 mg/m2 cisplatin was administered with a 79.9% CR. 1 mg oran GRAN is a suitable antiemetic therapy in moderately emetogenic chemotherapies.